NasdaqGM - Nasdaq Real Time Price USD
Trevi Therapeutics, Inc. (TRVI)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 5:35 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
43,173.0000
33,923.0000
29,907.0000
32,476.0000
32,489.0000
--
Operating Income
-43,173.0000
-33,923.0000
-29,907.0000
-32,476.0000
-32,489.0000
--
Net Non Operating Interest Income Expense
4,244.0000
4,357.0000
577.0000
-1,192.0000
-278.0000
--
Other Income Expense
145.0000
469.0000
142.0000
-293.0000
-9.0000
--
Pretax Income
-38,784.0000
-29,097.0000
-29,188.0000
-33,961.0000
-32,776.0000
--
Tax Provision
-11.0000
-32.0000
-36.0000
-21.0000
-18.0000
--
Net Income Common Stockholders
-38,773.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
--
Diluted NI Available to Com Stockholders
-38,773.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
--
Basic EPS
-0.38
-0.29
-0.45
-1.49
-1.77
--
Diluted EPS
-0.38
-0.29
-0.45
-1.49
-1.77
--
Basic Average Shares
99,845.6360
99,033.3730
64,541.9110
22,841.4810
18,546.7860
--
Diluted Average Shares
99,845.6360
99,033.3730
64,541.9110
22,841.4810
18,546.7860
--
Total Operating Income as Reported
-43,173.0000
-33,923.0000
-29,907.0000
-32,476.0000
-32,489.0000
--
Total Expenses
43,173.0000
33,923.0000
29,907.0000
32,476.0000
32,489.0000
--
Net Income from Continuing & Discontinued Operation
-38,773.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
--
Normalized Income
-38,773.0000
-29,065.0000
-29,005.1470
-34,021.9180
-32,749.0090
--
Interest Income
4,253.0000
4,748.0000
1,740.0000
10.0000
178.0000
--
Interest Expense
9.0000
391.0000
1,163.0000
1,202.0000
456.0000
--
Net Interest Income
4,244.0000
4,357.0000
577.0000
-1,192.0000
-278.0000
--
EBIT
-38,775.0000
-28,706.0000
-28,025.0000
-32,759.0000
-32,320.0000
--
EBITDA
-38,632.0000
-28,583.0000
-27,982.0000
-32,709.0000
-32,273.0000
--
Reconciled Depreciation
143.0000
123.0000
43.0000
50.0000
47.0000
--
Net Income from Continuing Operation Net Minority Interest
-38,773.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
--
Total Unusual Items Excluding Goodwill
-94.0000
--
-147.0000
82.0000
-9.0000
--
Total Unusual Items
-94.0000
--
-147.0000
82.0000
-9.0000
--
Normalized EBITDA
-38,632.0000
-28,583.0000
-27,835.0000
-32,791.0000
-32,264.0000
--
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
0.0000
--
Tax Effect of Unusual Items
--
--
-0.1470
0.0820
-0.0090
--
12/31/2019 - 5/7/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RZLT Rezolute, Inc.
4.8500
+2.32%
BNTC Benitec Biopharma Inc.
11.48
+2.32%
ATXS Astria Therapeutics, Inc.
11.46
-2.55%
VRDN Viridian Therapeutics, Inc.
24.98
+2.97%
TCRX TScan Therapeutics, Inc.
5.37
+2.09%
ELVN Enliven Therapeutics, Inc.
29.00
+3.50%
SLN Silence Therapeutics plc
17.99
-2.76%
OVID Ovid Therapeutics Inc.
1.2200
+4.27%
PRAX Praxis Precision Medicines, Inc.
73.20
-2.30%
MLYS Mineralys Therapeutics, Inc.
14.40
+3.75%